Purple Biotech Reported New Biomarker Findings From Phase 2 Study Of Its Lead Oncology Therapeutic Candidate CM24 In Combination With Bristol Myers Squibb's Nivolumab Plus Standard Of Care Chemotherapy
Portfolio Pulse from Benzinga Newsdesk
Purple Biotech has reported promising new biomarker findings from a Phase 2 study of its oncology therapeutic candidate CM24, in combination with Bristol Myers Squibb's Nivolumab and standard chemotherapy. The study identified potential biomarkers associated with improved overall survival in pancreatic ductal adenocarcinoma patients, supporting the efficacy of the CM24/nivolumab treatment.
September 18, 2024 | 10:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's Nivolumab, when combined with Purple Biotech's CM24, shows potential for improved survival in pancreatic cancer patients, highlighting the drug's efficacy in combination therapies.
The study highlights the efficacy of Nivolumab in combination with CM24, which could enhance Bristol Myers Squibb's reputation in oncology and potentially increase demand for Nivolumab in combination therapies.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
Purple Biotech's new biomarker findings from its Phase 2 study of CM24 show potential for improved survival in pancreatic cancer patients, supporting the efficacy of the CM24/nivolumab treatment.
The new biomarker findings suggest that CM24, in combination with Nivolumab, could significantly improve survival rates in pancreatic cancer patients. This positive data could boost investor confidence and potentially lead to increased interest and investment in Purple Biotech.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90